Skip to main content
SpringerLink
Log in

Clinical Significance of Pharmacokinetic Drug Interactions between Interferon-α and Antineoplastic Drugs

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The major problems in chemotherapy are occasional low response rates in patients despite favourable in vitro action, the development of drug resistance and long or short term adverse effects. Therefore, in the past decade efforts have been made to circumvent these problems by combining antineoplastic drugs with biomodulating or cytoprotective agents. Most of the clinically useful drug regimens consist of a cocktail of drugs with different mechanisms of action, and hence different toxicity profiles. Dose-limiting factors in regard to toxicity and therapeutic efficacy predominate, and it is therefore clinically essential to know whether or not a pharmacokinetic drug interaction occurs.

The introduction of interferon-α (IFNα) in chemotherapy is an alternative investigational approach to amplify the cytotoxicity of an antineoplastic drug in order to increase tumour response. Most of the clinical studies reported with IFNα provide useful information and identify major pharmacodynamic interactions, but only a few focus on and report potential pharmacokinetic interactions between antineoplastic drugs and IFNα in patients. The broad spectrum of antineoplastic drugs whose activity can be enhanced by IFNα argues for multiple levels of drug-drug interactions: protein binding (cisplatin), alteration in cellular uptake, modulation of drug target enzymes (dihydropyrimidine hydrogenase) and changes in biotransformation (tretinoin) or excretion. Pharmacokinetic and/or pharmacodynamic interactions may be beneficial (fluorouracil) or sometimes detrimental and coincidental (doxorubicin).

This article focuses on observed pharmacokinetic drug interactions between IFNα and antineoplastic drugs and discusses possible mechanisms of action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hochkeppel HK, Gruetter M, Horisberger MA, et al. Human IFN-alpha hybrids. Drags Future 1992; 17(10): 889–914

    Google Scholar 

  2. Richards JM. Sequential chemoimmune therapy for metastatic melanoma. Semin Oncol 1991; 5 Suppl. 7: 91–5

    Google Scholar 

  3. Richards JM. Therapeutic uses of interleukin-2 and lymphokine-activated killer cells. Blood Rev 1989; 3: 110–9

    Article  PubMed  CAS  Google Scholar 

  4. Dhingra K, Duvic M, Hymes S, et al. A phase-I clinical study of low-dose oral interferon-alpha. J Immunother 1993 Jul; 14(1): 51–5

    Article  CAS  Google Scholar 

  5. Wills RJ. Clinical pharmacokinetics of interferons. Clin Phar-macokinet 1990; 19(5): 390–9

    Article  CAS  Google Scholar 

  6. Chauvet CJ, Deweerdt C, Pivot-Dumarest C. Roferon A, Intron A: alpha-interferons. Lyon Pharm 1996; 47(1): 29–33

    Google Scholar 

  7. Bocci V. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. Crit Rev Ther Drug Carrier Syst 1992; 9: 91–133

    PubMed  CAS  Google Scholar 

  8. Bonetti A, Kim S. Pharmacokinetics of an extended-release human interferon alpha-2b formulation. Cancer Chemother Pharmacol 1993 Dec; 33(3): 258–61

    Article  PubMed  CAS  Google Scholar 

  9. Bornemann LD, Spiegel HE, Dziewanowska ZE, et al. Intravenous and intramuscular pharmacokinetics of recombinant leucocyte A interferon. Eur J Clin Pharmacol 1985; 28: 459–71

    Article  Google Scholar 

  10. Radwanski E, Perenthesis G, Jacobs S, et al. Pharmacokinetics of interferon-α-2b in healthy volunteers. J Clin Pharmacol 1987; 27: 432–5

    PubMed  CAS  Google Scholar 

  11. Wells RJ, Weck PK, Boehner RL, et al. Interferon in children with recurrent acute lymphocytic leukemia: a phase-I study of pharmacokinetics and tolerance. J Interferon Res 1988; 8: 309–18

    Article  PubMed  CAS  Google Scholar 

  12. Bocci V. Metabolism in protein anticancer agents. In: Powis G, editor. Anticancer drugs: antimetabolite metabolism and natural anticancer agents. Chap 9. Oxford: Pergamon Press Ltd., 1994: 402–8

    Google Scholar 

  13. Schüller J, Czejka MJ, Schernthaner G, et al. Pharmacokinetic aspects of interferon-α-2b after i.a. or i.p. administration. Semin Oncol 1992; 19(2): 98–104

    PubMed  Google Scholar 

  14. Berek JS, Hacker NF, Lichtenstein A, et al. Intraperitoneal recombinant alpha-IFN for ’salvage’ immunotherapy in stage-III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res 1985; 45: 4447–53

    PubMed  CAS  Google Scholar 

  15. Wills RJ, Dennis S, Spiegel HE, et al. Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clin Pharmacol Ther 1984; 35: 722–7

    Article  PubMed  CAS  Google Scholar 

  16. Guttermann JU, Fine S, Quesada J, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549–56

    Google Scholar 

  17. Dorr RT. Interferon-alpha in malignant and viral diseases — a review. Drags 1993 Feb; 45(2): 177–211

    Article  CAS  Google Scholar 

  18. Stadler WM, Kuzel TM, Raghavan D, et al. Metastatic bladder cancer: advances in treatment. Eur J Cancer 1997 Jan; 33: 23–6

    Article  Google Scholar 

  19. Ohwada S, Kobayashi I, Maemura M, et al. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer Lett 1996 Dec; 110(1-2): 149–54

    Article  PubMed  CAS  Google Scholar 

  20. Rohde D, Goertz M, Sikora R, et al. Inhibition of (metastatic) renal cell carcinoma in nude mice by gemcitabine with interferon-alpha. In: Rao RS, editor. Proceedings of the 11-15 International Cancer Congress 1994. Free Paper Posters. Bologna: Monduzzi Editore, 11–5

    Google Scholar 

  21. Vuoristo MS, Grohn P, Kellokumpu-Lethinen P, et al. Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 1995; 121(3): 175–80

    Article  PubMed  CAS  Google Scholar 

  22. Reinhold U, Bruske T, Kreysel HW. Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma. Eur J Cancer 1996 Jan; 32 A(1): 180

    Article  PubMed  CAS  Google Scholar 

  23. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukaemia in chronic phase. Blood 1995; 86(3): 906–16

    PubMed  CAS  Google Scholar 

  24. Kirchner HH, Atzpodien J, Poliwoda H. Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin-2 and interferon-alpha 2a. Med Klin 1996; 91 Suppl. 3: 44–9

    Google Scholar 

  25. Iaffaioli RV, Tortoriello A, Facchini G, et al. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Breast Cancer Res Treat 1995; 35(3): 243–8

    Article  PubMed  CAS  Google Scholar 

  26. Atzpodien J, Lopez-Hanninen E, Kirchner H, et al. Chemo-immunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995; 31A(6): 876–81

    Article  PubMed  CAS  Google Scholar 

  27. Foppoli M, Citterio G, Polastri D, et al. The feasibility of repetitive courses of high dose continuous infusion interleukin-2 and alpha-interferon with polychemotherapy in advanced malignant melanoma. Tumori 1995; 81(2): 102–6

    PubMed  CAS  Google Scholar 

  28. Moore DH, Valea F, Walton LA, et al. A phase I study of in-traperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1995; 59(2): 267–72

    Article  PubMed  CAS  Google Scholar 

  29. Feun LG, Savaraj N, Moffat F, et al. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 1995; 5(4): 273–6

    Article  PubMed  CAS  Google Scholar 

  30. Pass HW, Temeck BK, Kranda K, et al. A phase II trial investigating primary immuno-chemotherapy for malignant pleural mesothelioma and feasibility of adjuvant immuno-chemotherapy after maximal cytoreduction. Ann Surg Oncol 1995; 2(3): 214–20

    Article  PubMed  CAS  Google Scholar 

  31. Nordic Myeloma Study Group. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Intern Med 1996; 124(2): 212–22

    Google Scholar 

  32. Silva RR, Bascioni R, Rossini S, et al. A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced nonsmall cell lung cancer. Tumori 1996; 82(1): 68–71

    PubMed  CAS  Google Scholar 

  33. Sakata Y, Takemori H, Suzuki H. Chemotherapy for pancreatic cancer. Gan To Kagaku Ryoho 1996; 23(12): 1647–50

    PubMed  CAS  Google Scholar 

  34. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6(5): 467–76

    PubMed  CAS  Google Scholar 

  35. Ferrajoli A, Liberati AM, Caricchi P, et al. Interferon-alpha plus low dose cytosine arabinoside in advanced chronic myelogenous leukaemia patients. Eur J Haematol 1995; 55(3): 184–8

    Article  PubMed  CAS  Google Scholar 

  36. Bezwoda WR, Seymour L, Ruff P. Combined cytosine arabinoside plus interferon-alpha: 2. Clinical studies in leukemia and lymphoma. Int Oncol 1993 Mar; 2(3): 469–72

    CAS  Google Scholar 

  37. Palmieri G, Morabito A, Rea A, et al. Cytosine arabinoside plus alpha-interferon determine prolonged complete remissions in patients with aggressive non-Hodgkin’s lymphoma partially responsive to first line doxorubicin regimens. Br J Haematol 1994 Oct; 88(2): 421–3

    Article  PubMed  CAS  Google Scholar 

  38. Vuoristo MS. Complete responses and survival after polychemotherapy plus interferon-alpha with metastatic carcinoma. Melanoma Res 1996; 6(4): 331–6

    Article  PubMed  CAS  Google Scholar 

  39. Ron IG, Inbar MJ, Gutman M, et al. Recombinant interferon-alpha 2A in combination with dacarbazine in the treatment of metastatic malignant melanoma — analysis of long-term responding patients. Cancer Immunol 1993 Jul; 37(1): 61–6

    Article  CAS  Google Scholar 

  40. Peest D, Deicher H, Coldewey R, et al. A comparison of melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995; 31A(2): 146–51

    Article  PubMed  CAS  Google Scholar 

  41. Zervas K, Pouli A, Perifanis V, et al. Maintenance therapy with interferon-alpha versus interferon-alpha plus chemotherapy in multiple myeloma: the Greek Myeloma Study Group. Eur J Haematol 1996; 57(2): 142–8

    Article  PubMed  CAS  Google Scholar 

  42. Upham JW, Musk AW, VanHazel G, et al. Interferon-alpha and doxorubicin in malignant mesothelioma — a phase-II study. Aust NZ J Med 1993 Dec; 23(6): 683–7

    Article  CAS  Google Scholar 

  43. Sparano JA, Wadler S, Liebes L, et al. Phase I trial of cyclophosphamide, doxorubicin and 5-fluorouracil plus interferon-α-2b in patients with advanced breast cancer. Cancer Res 1993 Aug; 53: 3509–12

    PubMed  CAS  Google Scholar 

  44. Marshall ME, Wolf M, Crawford ED, et al. Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer Biother 1995 Fall; 10(3): 205–9

    Article  PubMed  CAS  Google Scholar 

  45. Wang J, Cao X, Zhang W, et al. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin. Leuk Res 1996; 20(5): 379–84

    Article  PubMed  CAS  Google Scholar 

  46. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant in-terferon-alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993 Nov; 329: 1608–14

    Article  PubMed  CAS  Google Scholar 

  47. Ganju V, Edmonson JH, Bruckner JC. Phase I study of combined alpha interferon, alpha difluorometholornithine and doxorubicin in advanced malignancy. Invest New Drugs 1994; 12(1): 25–7

    Article  PubMed  CAS  Google Scholar 

  48. Bandak S, Czejka MJ, Schueller J. Pharmacokinetic drug interaction between epirubicin and interferon-α-2b in serum and red blood cells. Drug Res 1995; 45(1): 212–5

    CAS  Google Scholar 

  49. Kok TC, van der Gaast A, Splinter TA. 13-Cis retinoic acid and alpha-interferon in advanced squamous cell cancer of oesophagus. Eur J Cancer 1997 Jan; 33(1): 165–6

    Article  PubMed  CAS  Google Scholar 

  50. Lygidakis NJ, Kosmidis P, Ziras N, et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 1995; 15(5): 467–72

    Article  PubMed  CAS  Google Scholar 

  51. Bokemeyer C, Kynast B, Harstrick A, et al. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1995; 35(4): 334–8

    Article  PubMed  CAS  Google Scholar 

  52. Mick R, Vokes EE, Lestingi TM, et al. Etoposide combined with interferon-α-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1996 Mar; 59(3): 349–59

    Article  PubMed  CAS  Google Scholar 

  53. Papo T, Piette JC, Hermine O. Treatment of the hypereosinophilic syndrome with interferon-alpha. Ann Intern Med 1995 Jul; 123: 155–6

    PubMed  CAS  Google Scholar 

  54. Daliani DD, Eisenberg PD, Weems J, et al. The results of a phase-II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 1995; 153(5): 1587–91

    Article  PubMed  CAS  Google Scholar 

  55. Noguchi S, Shuin T, Kubota Y, et al. Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal carcinoma. Hinyokika Kiyo 1995; 41(7): 517–20

    PubMed  CAS  Google Scholar 

  56. Kleeberg UR, Gawlik C, Broecker EB, et al. Interferon-alpha and fotemustine in patients with disseminated melanoma: a multicenter phase-II trial of the AIO phase I/II study group of the German Cancer Society. Onkologie 1995; 18(5): 456–61

    Article  Google Scholar 

  57. Jehn U, Potscher C, Heinemann V. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. Leuk Lymphoma 1995; 19(1-2): 153–7

    Article  PubMed  CAS  Google Scholar 

  58. Horowitz R, Wadler S. Modulation of 5FU/alpha-interferon with high dose continuous infusion hydroxyurea. J Infus Chemother 1995; 5(4): 212–4

    PubMed  CAS  Google Scholar 

  59. Amoroso D, Boccardo F, Balestrero M, et al. Megestrol acetate plus alpha-2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial. Breast Cancer Res Treat 1995; 33(3): 265–8

    Article  PubMed  CAS  Google Scholar 

  60. Cascinu S, Alessandroni P, Rossi D, et al. Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate and interferon-alpha in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1996; 38(4): 385–6

    Article  PubMed  CAS  Google Scholar 

  61. Tummarello D, Graziano F, Isidori P, et al. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, ad-riblastine, mitomycin-C) regimen: a phase II study. Cancer 1996; 77(11): 2251–7

    Article  PubMed  CAS  Google Scholar 

  62. Hand AMS, Husgafvelpursianinen K, Pelin K, et al. Interferon alpha and interferon gamma in combination with chemother-apeutic drugs — in vitro sensitivity studies in 4 human mesothelioma cell lines. Anti Cancer Drugs 1992 Dec; 3(6): 687–94

    Article  PubMed  CAS  Google Scholar 

  63. Duru F, Truncer M, Hicsonmez G. Prolonged hematological remission by mitoxantrone and interferon-alpha-2b in a child with resistant Philadelphia chromosome positive chronic my-elogenous leukemia. Eur J Haematol 1993 Sep; 51(3): 173–4

    Article  PubMed  CAS  Google Scholar 

  64. Rowinsky EK. Pharmacology and metabolism. In: McGuire WP, Rowinsky EK, editors. Paclitaxel in cancer treatment. New York: Marcel Decker, 1995: 91–119

    Google Scholar 

  65. Wadler S, Schwartz EL, Haynes H, et al. All-trans retinoic acid and interferon-α-2a in patients with metastatic or recurrent carcinoma of the uterine cervix. Cancer 1997 Apr; 79(8): 1574–80

    Article  PubMed  CAS  Google Scholar 

  66. Piamsomboon S, Termrungruanglert W, Kudelka AP, et al. Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literature. Anticancer Drugs 1996 Sep; 7(7): 800–4

    Article  PubMed  CAS  Google Scholar 

  67. Toma S, Airoldi M, Palumbo R, et al. Combination of alpha interferon 2a and 13-cis-retinoic acid in recurrent, pretreated squamous-cell carcinoma of head and neck. Int J Cancer 1997 Feb; 70(4): 491–3

    Article  PubMed  CAS  Google Scholar 

  68. Hoffmann W, Schiebe M, Hirnle P, et al. 13-Cis retinoic acid and interferon-alpha +/− irradiation in the treatment of squamous cell carcinomas. Int J Cancer 1997 Feb; 70(4): 475–7

    Article  PubMed  CAS  Google Scholar 

  69. Fleming GF, O’Brien SM, Hoffman PC, et al. Phase I study of treatment with oral 13-cis retinoic acid, subcutaneous interferon alpha-2a, cisplatin, and 24-hour infusion 5-fluoro-ura-cil/leucovorin. Cancer Chemother Pharmacol 1997; 39(3): 227–32

    Article  PubMed  CAS  Google Scholar 

  70. Paolorossi F, Villa S, Barni S, et al. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cancer patients progressed under interleukin subcutaneous immunotherapy. Tumori 1995; 81(1): 45–7

    PubMed  CAS  Google Scholar 

  71. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473–86

    PubMed  CAS  Google Scholar 

  72. Kang Y, Perry RR. Effect of α-interferon on p-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 1994 Jun; 54: 2952–8

    PubMed  CAS  Google Scholar 

  73. Eksborg S, Mattson K. Pharmacokinetics of epirubicin in man: non-influence of alpha interferon. Med Oncol Tumor Phar-macother 1988; 5(2): 131–3

    CAS  Google Scholar 

  74. Serretta V, Corselli G, Piazza B, et al. Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin — a pilot study. Urol Res 1993 Sep; 21(5): 353–7

    Article  PubMed  CAS  Google Scholar 

  75. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant α-2a-interferon: an active regimen against advanced colorectal cancer. J Clin Oncol 1989; 7: 1769–75

    PubMed  CAS  Google Scholar 

  76. Brestescher C, Pautier P, Farge D. Chemotherapy and cardiotoxicity. Ann Cardiol Angeiol 1995; 44(8): 443–7

    CAS  Google Scholar 

  77. Pittman K, Perren T, Ward U, et al. Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Ann Oncol 1993; 4(6): 515–6

    PubMed  CAS  Google Scholar 

  78. Meadows L, Lindley C, Bernard S, et al. Interferon-alpha increases 5-fluorouracil plasma levels 64-fold within one hour: results of a phase I study. J Interferon Res 1990; II: 6–31

    Google Scholar 

  79. Greco FA, Figlin R, York M, et al. Phase III randomized study to compare interferon alpha-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996 Oct; 14(10): 2674–81

    PubMed  CAS  Google Scholar 

  80. Hill M, Norman A, Cunningham N, et al. Royal Marsden phase III trial of fluorouracil with or without interferon-alfa-2b in advanced colorectal cancer. J Clin Oncol 1995 Jun; 13(6): 1297–302

    PubMed  CAS  Google Scholar 

  81. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995 Apr; 13(4): 921–8

    Google Scholar 

  82. Schneider M, Etienne MC, Milano G, et al. Phase II trial of cisplatin, fluorouracil and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995 Jul; 13(7): 1656–62

    PubMed  CAS  Google Scholar 

  83. Houghton JA, Morton Cl, Adkins D A, et al. Locus of interaction among 5-fluorouracil, leucovorin and interferon-α-2a in colon carcinoma cells. Cancer Res 1995 Sep; 53: 4243–50

    Google Scholar 

  84. Houghton JA, Adkins DA, Rahman A, et al. Interaction between 5-fluorouracil, [6RS]-leucovorin and recombinant interferon-α-2a in cultured colon adenocarcinoma cells. Cancer Commun 1991; 3(7): 225–312

    PubMed  CAS  Google Scholar 

  85. Moore MJ, Ehrlichman C, Kaizer L, et al. A phase-II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer. Anticancer Drugs 1993; 4: 555–7

    Article  PubMed  CAS  Google Scholar 

  86. Grem JL, Yee LK, Allegra CJ, et al. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin and interferon-alpha. J Natl Cancer Inst 1992 Dec; 84(23): 1820–5

    Article  PubMed  Google Scholar 

  87. Cascinu S, Delferro E, Ligi M, et al. A phase I trial of 5-fluoro-uracil, leucovorin and interferon-alpha-2b administered by 24 h infusion in metastatic colorectal carcinoma. Anticancer Drugs 1996 Jul; 7(5): 520–4

    Article  PubMed  CAS  Google Scholar 

  88. Kreuser ED, Hilgenfeld RU, Matthias M, et al. A phase I trial of interferon-alpha-2b with folinic acid and 5-fluorouracil administered by 4 hour infusion in metastatic colorectal carcinoma. Semin Oncol 1992; 19(2 Suppl. 3): 197–203

    PubMed  CAS  Google Scholar 

  89. Vokes EE, Ratain MJ, Mick R, et al. Cisplatin, fluorouracil and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacological analysis. J Clin Oncol 1993 Feb; 11(2): 360–8

    PubMed  CAS  Google Scholar 

  90. Danhauser LL, Freiman JH, Gilchrist TL, et al. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alpha-2b in patients with advanced cancer. J Clin Oncol 1993 Apr; 11(4): 751–61

    PubMed  CAS  Google Scholar 

  91. Czejka MJ, Schueller J, Schernhammer E, et al. Drug interaction between interferon-alpha-2b and fluorouracil during continuous intravenous 5FU infusion. Pharmazie 1995 Jun; 50: 416–9

    PubMed  CAS  Google Scholar 

  92. Sparano JA, Wadler S, Diasio RB, et al. Phase I trial of low-dose, prolonged continuous infusion of fluorouracil plus in-terferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993 Aug; 11(8): 1609–17

    PubMed  CAS  Google Scholar 

  93. Schüller J, Czejka MJ, Armbruster C, et al. Pharmakokinetische Aspekte der Biomodulation von 5-Fluorouracil durch Interferon alpha-2b in der Behandlung des fortgeschrittenen kolorektalen Karzinoms. Acta Chir Austr 1991; 5/6: 214–7

    Article  Google Scholar 

  94. Schiiller J, Czejka MJ, Schernthaner G, et al. Influence of interferon alpha-2b with or without folinic acid on pharmaco-kinetics of fluorouracil. Semin Oncol 1992 Apr; 19 Suppl. 2: 93–7

    Google Scholar 

  95. Czejka MJ, Jaeger W, Schueller J, et al. Clinical pharmacoki-netics of 5-fluorouracil: influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Drug Res 1993 Mar; 43(3): 387–90

    CAS  Google Scholar 

  96. Sparano JA, Wadler S, Schwartz EL, et al. Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer. Int J Clin Pharmacol Res 1993; 13(1): 1–9

    PubMed  CAS  Google Scholar 

  97. Czejka MJ, Jaeger W, Schueller J, et al. Pharmacokinetic aspects of the combination of interferon-alpha-2b and folinic acid with fluorouracil. Drug Res 1991; 41(8): 860–3

    CAS  Google Scholar 

  98. Seymour MT, Patel N, Johnston A, et al. Lack of effect of in-terferon-alpha-2a upon fluorouracil pharmacokinetics. Br J Cancer 1994; 70: 724–8

    Article  PubMed  CAS  Google Scholar 

  99. Czejka MJ, Schueller J, Fogl U, et al. Influence of interferon-alpha-2b on the blood plasma levels of intra-arterially administered fluorouracil. Pharmazie 1991 Nov; 46: 817–8

    PubMed  CAS  Google Scholar 

  100. Kase S, Kubota T, Watanabe M, et al. Recombinant human interferon alpha-2a increases the antitumor activity of 5-fluorouracil on human colon carcinoma xenograft CO-4 without any change in 5-FU pharmacokinetics. Anticancer Res 1995 Feb; 15(1): 153–5

    PubMed  CAS  Google Scholar 

  101. Kamm YJL, Rietjens IMCM, Vervoort J, et al. Effect of modulators on 5-fluorouracil metabolite patterns in colon carcinoma determined by in-vitro F-19 nuclear magnetic resonance spectroscopy. Cancer Res 1994 Aug; 54(16): 4321–6

    PubMed  CAS  Google Scholar 

  102. Czejka MJ, Jaeger W, Schueller J, et al. Influence of different doses of interferon-alpha-2b on the blood plasma levels of 5-fluorouracil. Eur J Drug Metab Pharmacokinet 1993; 18: 247–50

    Article  PubMed  CAS  Google Scholar 

  103. Moore MJ, Kaizer L, Ehrlichman C, et al. A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. Cancer Chemother Pharmacol 1995; 37: 86–90

    Article  PubMed  CAS  Google Scholar 

  104. Vokes EE, Mick R, Kies MS, et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996; 14(5): 1663–71

    PubMed  CAS  Google Scholar 

  105. Milano G, Etienne MC, Renie N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 12(6): 1291–5

    PubMed  CAS  Google Scholar 

  106. Paris AK, Tsavaris N, Desmothenis S, et al. Fluorouracil and leucovorin with and without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase-in trial. J Clin Oncol 1996 Oct; 14(10): 2682–7

    Google Scholar 

  107. Milano G, Fischel JL, Etienne MC, et al. Inhibition of dihydropyrimidine dehydrogenase by alpha interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol 1994; 34(2): 147–52

    Article  PubMed  CAS  Google Scholar 

  108. Chu E, Zinn S, Boarman D, et al. Interaction of α-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990; 50: 5834–40

    PubMed  CAS  Google Scholar 

  109. Van der Wilt CL, Pinedo HM, Smid K, et al. Effect of folinic acid on fluorouracil activity and expression of thymidilate synthase. Semin Oncol 1992; 19 Suppl. 3: 16–25

    Google Scholar 

  110. Horowitz RW, Heerdt BG, Hu X, et al. Combination therapy with 5FU and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res 1997 Aug; 3: 1317–22

    PubMed  CAS  Google Scholar 

  111. Schwartz EL, Baptiste N, O’Connor CJ, et al. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and desoxy-ribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 1994 Mar; 54: 1472–8

    PubMed  CAS  Google Scholar 

  112. Schueller J, Cassidy J, Reigner BG, et al. Tumor selectivity of Xeloda in colorectal cancer patients [abstract no. 797]. Proc Am Soc Clin Oncol 1997; 16: 797

    Google Scholar 

  113. Ishikawa T, Utoh M, Sawada N, et al. Tumor selectivity of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenogafts. Biochem Pharmacol 1998 Apr; 55(7): 1091–7

    Article  PubMed  CAS  Google Scholar 

  114. Grem JL, McAtee N, Murphy RF, et al. A pilot study of α-lb- interferon in combination with fluorouracil, leucovorin and α-2a-interferon. Clin Cancer Res 1997 Jul; 3: 1125–34

    PubMed  CAS  Google Scholar 

  115. Grem JL. 5-Fluorinatedpyrimidines. In: Chabner A, Longo DL, editors. Cancer chemotherapy biotherapy: principles and practice. Philadelphia: Lippincott-Raven Publishers, 1996: 149–210

    Google Scholar 

  116. Czejka MJ, Schueller J, Weiss C, et al. Disposition of 5-formyl-and 5-methyl-tetrahydro folic acid in serum after i.V. bolus of calcium folinate: pharmacokinetic drug interaction with pre-administered interferon-alpha-2b. Eur J Drug Metabol Pharmacokinet 1995; 20(4): 255–62

    Article  CAS  Google Scholar 

  117. Sinnige HAM, Buter J, deVries EGE, et al. Phase I-II study of the addition of alpha-2a-interferon to 5-fluorouracil/leucovorin: pharmacokinetic interaction of alpha-2a interferon and leucovorin. Eur J Cancer 1993; 29A(12): 1715–20

    Article  PubMed  CAS  Google Scholar 

  118. Nakazawa Y, Chiba K, Imota N, et al. Serum folic acid levels and antipyrine clearance rates in smokers and non-smokers. Drug Alcohol Depend 1983; 11: 201–7

    Article  PubMed  CAS  Google Scholar 

  119. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985; 30: 145–55

    Article  PubMed  CAS  Google Scholar 

  120. Vokes EE, Haraf DJ, Hoffmann PC. Escalating doses of inter-feron-alpha-2a with cisplatin and concomitant radiotherapy — a phase-I study. Cancer Chemother Pharmacol 1993 Dec; 33(3): 203–9

    Article  PubMed  CAS  Google Scholar 

  121. Margolin KA, Doroshow JH, Akman SA, et al. Cisplatin and α-interferon in advanced malignant melanoma. J Clin Oncol 1992 Oct; 10(10): 1574–8

    PubMed  CAS  Google Scholar 

  122. Gosland MP, Goodin S, Yokel RA. A phase-I trial of 5-day continuous infusion cisplatin and interferon-α. Cancer Chemother Pharmacol 1995; 37: 39–46

    Article  PubMed  CAS  Google Scholar 

  123. John WJ, Goodin S, Gosland MP, et al. Continuous infusion cisplatin and interferon-alpha in the treatment of advanced malignancy: phase-I trial. American Society of Health System Pharmacists Midyear Clinical Meeting 1992 Dec; P-183R

  124. French RC, Bowman A, MacLeod KG, et al. Effect of recombinant interferon-α on the activity of cisdiamminedichloroplatinum(II) in human non-small cell lung cancer xenografts. Cancer Invest 1995; 13(6): 595–603

    Article  PubMed  CAS  Google Scholar 

  125. Moochhala SM, Renton KW. Induction and depression of cytochrome P-450—dependent mixed-function oxidase by a cloned consensus of αIFN in the hamster. Biochem Pharmacol 1989; 38: 439–47

    Article  PubMed  CAS  Google Scholar 

  126. Cascinu S, Fedeli A, Catalano G, et al. Etoposide, leucovorin, 5-fluorouracil and interferon-alpha-2b in elderly gastric cancer patients — a pilot study. Cancer Chemother Pharmacol 1994 Apr; 34(1): 72–4

    Article  PubMed  CAS  Google Scholar 

  127. Halme M, Maasilta PK, Pyrhonen SO, et al. Interferons combined with chemotherapy in the treatment of stage III-IV nonsmall lung cancer — a randomized study. Eur J Cancer 1994; 30A(l): 11–5

    Article  PubMed  CAS  Google Scholar 

  128. Hande RK. Etoposide pharmacology. Semin Oncol 1992; 19: 3–9

    PubMed  CAS  Google Scholar 

  129. Stewart CF, Pieper JA, Arbruck SG, et al. Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 1989; 45: 4955–7

    Article  Google Scholar 

  130. Wildschwendter M, Daxenbichler G, Bachmair F, et al. Interaction of retinoic acid and interferon-alpha in breast cancer cell lines. Anticancer Res 1996; 16(1): 369–74

    Google Scholar 

  131. Castaigne S, Chomienne C, Daniel MT, et al. All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990; 76: 1704–9

    PubMed  CAS  Google Scholar 

  132. Marth C, Widschwendter M, Taxenbichler G. Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and interferons in breast cancer. J Steroid Biochem Mol Biol 1993 Dec; 47(1-6): 123–6

    Article  PubMed  CAS  Google Scholar 

  133. Bonhommefaivre L, Paule B, Urien S, et al. Pharmacokinetics of all-trans retinoic acid in patients with renal cancer concom-itantly treated with interferon alpha-2a. Int J Pharmaceutics 1996 May; 134(1-2): 99–104

    Article  CAS  Google Scholar 

  134. Lazzarino M, Corso A, Regazzi MB, et al. Modulation of all trans retinoic acid pharmacokinetics in acute leukemia by prolonged interferon-alpha therapy. Br J Haematol 1995 Aug; 90(4): 928–30

    Article  PubMed  CAS  Google Scholar 

  135. Lazzarino M, Regazzi MB, Corso A. Clinical relevance of alltrans retinoic acid pharmacokinetics and its modulation in acute promyelotic leukemia. Leuk Lymphoma 1996 Nov; 23(5-6): 539–43

    Article  PubMed  CAS  Google Scholar 

  136. Treat J, Friedland D, Luginbuhl W, et al. Phase-II trial of all-trans retinoic acid in metastatic non-small cell lung cancer. Cancer Invest 1996; 14(5): 415–20

    Article  PubMed  CAS  Google Scholar 

  137. Frolik CA, Roller PP, Roberts AB, et al. in vitro and in vivo metabolism of all-trans and 13-cis retinoic acid in hamsters. J Biol Chem 1980; 255: 8057–62

    PubMed  CAS  Google Scholar 

  138. Hirschel-Scholz S, Siegenthaler G, Saurat JH. Ligand specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP). Eur J Clin Invest 1989; 19: 220–7

    Article  PubMed  CAS  Google Scholar 

  139. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid x receptor ligand. J Clin Oncol 1997 Feb; 15(2): 790–5

    PubMed  CAS  Google Scholar 

  140. Ehrsson H, Eksborg S, Wallin I, et al. Oral melphalan pharmacokinetics: influence of interferon induced fever. Clin Pharmacol Ther 1990; 47: 86–90

    Article  PubMed  CAS  Google Scholar 

  141. Reynolds JEF, editor. Martindale — the extra pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989: 580–657

    Google Scholar 

  142. Weiner MW, Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed Proc 1983; 42: 2974–8

    PubMed  CAS  Google Scholar 

  143. Gilman AG, Wall TW, Nies AS, et al., editors. Appendix II: design and optimization of dosage regimens: pharmacoki- netic data. In: Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1650–735

  144. Schellens JHM, Pronk LC, Verweij J. Emerging drug treatments for solid tumors. Drugs 1996 Jan; 51(1): 45–72

    Article  PubMed  CAS  Google Scholar 

  145. Czejka MJ, Schueller J. Bindung von 5-Fluorouracil an Serumproteinfraktionen, Erythrozyten und Ghosts unter in vitro Bedingungen. Arch Pharm 1992; 325: 69–71

    Article  CAS  Google Scholar 

  146. Wong SL, Awni WM, Cavanaugh JH, et al. The pharmacokinetics of a single oral dose of zileutin 200 to 800mg, its enantiomers and its metabolites in healthy volunteers. Clin Pharmacokinet 1995; 29 Suppl. 2: 9–21

    Article  Google Scholar 

  147. Sasaki Y, Morita M, Tamura T, et al. In vitro and in vivo protein binding of the camptothecin analog CPT-11 and its metabolite SN38. Proc Annu Meet Jpn Cancer Assoc 1990; 49: 397

    Google Scholar 

  148. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-des-methyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989 Apr; 49(8): 2175–83

    PubMed  CAS  Google Scholar 

  149. Herben VM, ten Bokkel Huinink WW, et al. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996 Aug; 31(2): 85–102

    Article  PubMed  CAS  Google Scholar 

  150. Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995 Oct; 34(42): 1322–8

    Article  Google Scholar 

  151. Van Wauwe JP, Coene MC, Goossens J, et al. Effects of cyto-chrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990; 252: 365–9

    Google Scholar 

  152. Sewell GJ. Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Med Oncol 1995 Mar; 12: 9–14

    Article  PubMed  CAS  Google Scholar 

  153. Van Meerten E, Verweij J, Schellens JHM. Antineoplastic agents: drug interactions of clinical significance. Drug Saf 1995; 12(3): 168–82

    Article  Google Scholar 

  154. Kivisto KT, Kroemer HK, Eichelbaum M. The role of cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40(6): 523–30

    Article  PubMed  CAS  Google Scholar 

  155. Loadman PM, Bibby MC. Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet 1994; 26(6): 486–500

    Article  PubMed  CAS  Google Scholar 

  156. Okuno H, Kitao Y, Takasu M, et al. Depression of drug metabolism activity in the human liver by interferon-α. Eur J Clin Pharmacol 1990; 39: 365–7

    Article  PubMed  CAS  Google Scholar 

  157. Cribb AE, Delaporte E, Kim SG, et al. Regulation of cyto-chrome P-4501A and cytochrome P-4502E induction in the rat during the production of interferon alpha/beta. J Pharmacol Exp Ther 1994 Jan; 268(1): 487–94

    PubMed  CAS  Google Scholar 

  158. Ansher SS, Puri RK, Thompson WC, et al. The effects of interleukins and α-interferon administration on hepatic drug metabolism in mice. Cancer Res 1992; 52: 262–6

    PubMed  CAS  Google Scholar 

  159. Bertini R, Bianchi M, Villa P, et al. Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin-1 and tumor necrosis factor: a comparison with lymphotoxin and interferon. J Immunopharmacol 1988; 10: 525–30

    Article  CAS  Google Scholar 

  160. Donato MT, Herrero E, Gomezlechon MJ, et al. Inhibition of monooxygenase activities in human hepatocytes by interferons. Toxicol In Vitro 1993 Jul; 7(4): 481–5

    Article  PubMed  CAS  Google Scholar 

  161. Delaporte E, Cribb AE, Renton KW. Interferon mediated changes in the expression of CYP1A1 in human B lymphoblastoid (AHH-1TK+/−) cells. Can J Physiol Pharmacol 1995 Dec; 73(12): 1692–7

    Article  PubMed  CAS  Google Scholar 

  162. Abdel-Razzak Z, Layer P, Fautrel A, et al. Cytokines down-regulate expression of majorcytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993 Oct; 44(4): 707–15

    PubMed  CAS  Google Scholar 

  163. Piscitelli SC, Reiss WG, Figg WD, et al. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin Pharmacokinet 1997 May; 32(5): 368–81

    Article  PubMed  CAS  Google Scholar 

  164. Piscitelli SC, Amantea MA, Vogel S, et al. Effect of cytokines on antiviral pharmacokinetics: alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrob Agents Chemother 1996 Jan; 40: 161–5

    PubMed  CAS  Google Scholar 

  165. Israel BC, Blouin RA, Mclntyre W, et al. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993 Sep; 36(3): 229–35

    Article  PubMed  CAS  Google Scholar 

  166. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986; 22: 610–4

    Article  PubMed  CAS  Google Scholar 

  167. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987; 2: 939–41

    Article  PubMed  CAS  Google Scholar 

  168. Jonkman JH, Nicholson KG, Farrow PR, et al. Effect of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989; 27: 796–802

    Article  Google Scholar 

  169. Huang ZQ, Fasco MJ, Figge HL, et al. Expression of cyto-chromes P450 in human breast tissue and tumors. Drug Meta-bol Dispos 1996 Aug; 24(8): 899–905

    CAS  Google Scholar 

  170. Cossum PA. Role of the red blood cell in drug metabolism. Biopharm Drug Dispos 1988; 9: 321–36

    Article  PubMed  CAS  Google Scholar 

  171. Pfeiffer S. Pharmacokinetic drug interactions: parti. Pharmazie 1995; 50: 163–79

    Google Scholar 

  172. Powell SJ, Sewell GJ. The pharmacokinetics of ifosfamide and its enantiomers in continuous infusion regimens [editorial]. J Pharm Pharmacol 1992; 44 Suppl.: 1060

    Google Scholar 

  173. Workman P. Design of novel bioreductive drugs. In: Workman P, editor. New approaches to cancer pharmacology; drug design and development. London: Springer Verlag, 1992: 61–74

    Chapter  Google Scholar 

  174. Hagemann P, Reimann IW, editors. Arzneimittel und Laborwerte. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1992: 121

    Google Scholar 

  175. Product information. Intron AŖ. Aesca Pharmaceuticals. No. 1-18184; Vienna, Austria: 1992

  176. Renton KW. Alteration of drug biotransformation during the operation of host defense mechanism in humans. In: Jeffrey EH, editor. Human drug metabolism — from molecular biology to man. Boca Raton: CRC Press Inc., 1993: 143–51

    Google Scholar 

  177. Levi F, Soussan A, Adam R, et al. Programmable in-time pumps for chronotherapy of patients with colorectal cancer with 5-day circadian modulated venous infusion of 5-fluorouracil [abstract no. A429]. Proc Am Soc Clin Oncol 1989; 8: 8

    Google Scholar 

  178. Levi F, Benavides M, Chevelle C, et al. Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol 1990; 8: 705–14

    PubMed  CAS  Google Scholar 

  179. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase-II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992; 69: 893–900

    Article  PubMed  CAS  Google Scholar 

  180. Levi F. Chronopharmacology and chronotherapy of cancers. Pathol Biol 1996 Sep; 44(7): 631–44

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmaceutical Chemistry, Pharmacokinetic Department, University of Vienna, Althanstrasse 14, A-1090, Vienna, Austria

    Martin J. Czejka, Johannes Schueller, Heidi Kletzl & Silvia Strauch

  2. Department of Internal Medicine I and Oncology, Hospital Rudolfstiftung, Vienna, Austria

    Catherina Pietrzak

Authors
  1. Martin J. Czejka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Schueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heidi Kletzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Strauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Catherina Pietrzak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin J. Czejka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czejka, M.J., Schueller, J., Kletzl, H. et al. Clinical Significance of Pharmacokinetic Drug Interactions between Interferon-α and Antineoplastic Drugs. BioDrugs 11, 87–101 (1999). https://doi.org/10.2165/00063030-199911020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911020-00003

Keywords

Search

Navigation